Mutations in epidermal growth factor receptor (EGFR) kinase domain associate with clinical responses to EGFR inhibitors and are frequently observed in non-small cell lung cancer (NSCLC) patients in East Asian populations. Clinically identified EGFR mutations cause constitutive receptor activation. The activating mechanisms were unclear but appeared to be different among EGFR mutants. We found that EGFR mutants had different sensitivity to an Src inhibitor PP2. S768I and L861Q mutants were less sensitive to Src suppression than others. Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. In contrast, cells expressing EGFR-L858R or exon 19 deletion mutants were more sensitive to PP2 than cells expressing wild-type EGFR. Interestingly, EGFR with exon 19-deletion/T790M double mutations, which was resistant to gefitinib, remained sensitive to PP2. Taken together, our data indicate that Src inhibitors might be effective in treating NSCLC harboring specific types of EGFR mutations.
Introduction
Epidermal growth factor receptor (EGFR), a member of the ErbB family, is important in the regulation of growth, differentiation and survival of various cell types. Ligand binding to EGFR results in receptor dimerization, activation of tyrosine kinase domain and phosphorylation of carboxyl terminal tyrosine residues. The tyrosine-phosphorylated motifs of EGFR recruit various adaptors or signaling molecules to propagate the stimulating signals to different downstream pathways (Burgess et al., 2003; Citri and Yarden, 2006) .
Co-expression of Src, a non-receptor tyrosine kinase, with EGFR synergistically induces cell transformation (Biscardi et al., 2000; Ishizawar and Parsons, 2004) . Src phosphorylates EGFR at tyrosine (Y) 845, a residue located at the activation loop of EGFR kinase domain (Biscardi et al., 1999) . Phosphorylation on the Y845-homologous residues in other tyrosine kinases, such as platelet-derived growth factor receptor, insulin receptor and fibroblast growth factor receptor (FGFR) are required for the optimal activation of these kinases (Biscardi et al., 2000; Ishizawar and Parsons, 2004) . Structural analyses of tyrosine kinases show that phosphorylation at the Y845-homologous residues cause the positioning of the activation loop in a conformation that promotes the binding of adenosine triphosphate (ATP) and substrates (Biscardi et al., 2000) . However, the importance of Y845 phosphorylation by Src for EGFR activation remains controversial (Biscardi et al., 1999; Stamos et al., 2002; Burgess et al., 2003) .
EGFR overexpression is detected in various types of malignancy (Burgess et al., 2003; Citri and Yarden, 2006) ; therefore, EGFR-tyrosine kinase is a promising therapeutic target. Orally active small molecules against EGFR (for example, gefitinib and erlotinib) show evident antitumor effects in various cancers, particularly in non-small cell lung cancer (NSCLC) (Herbst and Bunn, 2003; Nakagawa et al. 2003; Gazdar et al., 2004) . Beneficial responsiveness to EGFR-targeting chemicals in NSCLC patients is closely associated with EGFR mutations in the kinase domain (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . These studies concluded that EGFR mutation, rather than EGFR overexpression, is the determining factor for responsiveness to gefitinib in NSCLC.
Previously, we reported a high mutation rate for EGFR in Taiwanese NSCLC patients (38.6%, 39/101) (Huang et al., 2004) . Others also showed high EGFR mutation rates in the East Asian populations (Kosaka et al., 2004; Chou et al., 2005; Shigematsu et al., 2005) . The L858R mutation and small deletions (E746-A750 deletion and others) in exon 19 are two major types of mutations; however, other point mutations, insertions and double mutants were also repetitively observed in NSCLC patients (Huang et al., 2004; Kosaka et al., 2004; Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . As EGFR mutations disperse within the kinase domain, the biochemical properties of these mutations and the sensitivity of these mutants to EGFR-targeting therapy are not identical (Chen et al., 2006) .
In this study, we showed that different EGFR mutants have varied sensitivity to an Src inhibitor, PP2. S768I and L861Q mutants were most resistant to suppression of Src. In contrast, cells expressing EGFR L858R and exon 19 deletion mutants were more sensitive to PP2 than cells expressing wild-type EGFR. Exon 19 deletion/T790M double mutant, a gefitinibresistant EGFR variant, remained sensitive to PP2. Our data indicate that clinically identified EGFR mutants have distinct activation mechanisms, and that Src is a potential therapeutic target for NSCLC harboring specific types of EGFR mutations.
Results

Mutant EGFRs have different sensitivity to an Src inhibitor PP2 in H1299 cells
We focused on active EGFR mutants that occurred repetitively in NSCLC. The mutated residues were scattered within the EGFR kinase domain (Supplementary Figure 1 ). These EGFR mutants did not have increasing dimerization, suggesting that the mechanism(s) leading to constitutive activation of EGFR mutants was downstream of receptor dimerization (Supplementary Figure 2 ). Then, we tested a hypothesis that these active EGFR mutants had different levels of dependence on Src for their activation. H1299 cells expressing various EGFR mutants were treated with an inhibitor to Src family kinases, PP2 (Hanke et al., 1996) . Autophosphorylation (on Y1068) of wild-type EGFR as well as variants harboring L858R, E746-A750 deletion (del), E709G or G719S mutation was greatly diminished by PP2. In contrast, residual phosphorylation could be detected in S768I and L861Q mutants even at 20 mM of PP2 treatment (Figure 1) .
To test whether PP2 acted on EGFR and its mutants directly, we examined the effect of PP2 in inhibiting EGFR mutants in vitro. Using immunocomplex kinase assays, we did not observe a directly inhibitory effect of PP2 on EGFR variants (Figure 2 ), indicating that the differential, inhibitory effects of PP2 on EGFR variants in cells were not due to direct EGFR inhibition. Moreover, EGFR-selective inhibitor AG1478 (10 mM) completely suppressed phosphorylation of all EGFR variants (Supplementary Figure 3) , indicating that all H1299-derivative lines were capable of de-phosphorylating EGFR efficiently. Therefore, the differential inhibitory effects found in PP2 treatment might not result from different efficacy of EGFR de-phoshorylation in H1299 cells. There was no positive or negative correlation between Src activity and sensitivity to PP2 in H1299 derivatives. This was determined by examining Src phosphorylation at Y416 (activating site) and Y527 (inhibitory site) as well as by measuring Src activity using a gluthathione-S-transferase-EGFR (amino acids 927-1121) fusion as a substrate (Supplementary Figure 4) . EGFR-S768I and L861Q mutants phosphorylate Y869(845) in the absence of Src activity A PP2 dose-dependent assay showed no evident decrease in Src auto-phosphorylation (Y416) in H1299 cells (Figure 3a) , which could be due to the slow Src de-phosphorylation by phosphatases in H1299 cells. However, EGFR phosphorylation at Y869 (Y845 in Varied sensitivity to Src suppression in EGFR mutants Y-N Fu et al matured EGFR without the signal peptide), the Srctargeting residue, was decreased by PP2 at concentrations higher than 5 mM in cells expressing wild-type, L858R, deletion, E709G and G719S mutants, indicating efficient Src suppression (Figure 3a) . Interestingly, Y869 (845) phosphorylation of S768I and L861Q mutants could not be completely abolished by PP2 (Figure 3a) . However, Src-dependent phosphorylation of focal adhesion kinase at Y576/577 was equally, efficiently abolished by PP2 in cells expressing wild-type EGFR, S768I or L861Q mutant ( Figure 3b ). This result indicated that Src activity was suppressed by PP2 in H1299 cells containing S768I and L861Q mutants as in other H1299 derivatives. Additionally, we found that immunoprecipitated S768I and L861Q mutants showed stronger Y869 (845) phosphorylation in vitro than did wild-type EGFR ( Figure 3c ). Addition of PP2 did not abolish this in vitro phosphorylation, suggesting that coprecipitated Src, if existed, was not involved (Figure 3c ).
The collective data indicated that EGFR-S768I and L861Q mutants might be able to phosphorylate themselves at Y869 (845) in the absence of Src activity.
EGFR mutants have different levels of dependence on Y869 (Y845) phosphorylation
We also examined whether Y869 (845) phosphorylation was important for the constitutive activation of EGFR mutants. The double-mutated receptors containing Y869 (845)F mutation were expressed in H1299 cells and their phosphorylation levels, normalized by the receptor levels, were compared with that of parental single mutants ( Figure 4a ). We found that Y869 (845)F mutation greatly decreased auto-phosphorylation at Y1068 of wild-type receptor and EGFR variants harboring L858R, exon 19 deletion, E709G or G719S mutation. Interestingly, S768I and L861Q mutants were relatively insensitive to Y869 (845)F mutation Figure 2 PP2 does not have a directly inhibitory effect on EGFR variants. H1299 cells expressing various EGFRs were treated with an EGFR inhibitor AG1478 (10 mM) to remove the basal phosphorylation of receptors before extract preparation. EGFR proteins were immunoprecipitated and subjected to in vitro kinase assays (KA) in the presence or absence of PP2 (10 mM) for 1 h. The autophosphorylation levels of EGFR proteins were examined by western blot assays using anti-phospho-EGFR (Y1068), anti-phosphoTyrosine (4G10) and anti-myc antibodies. EGFR, epidermal growth factor receptor. (845) were examined by western blotting using phosphorylation-specific antibodies. (b) Samples of H1299 cells expressing wildtype EGFR, S768I or L861Q mutant were examined for phosphorylation of FAK at Y576/577. (c) In vitro EGFR assays for wild-type, S768I and L861Q EGFR were performed as described in Figure 2 . The auto-phosphorylation EGFR proteins were examined by western blot assays using anti-phospho-EGFR (Y845) and anti-myc antibodies. EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase.
Varied sensitivity to Src suppression in EGFR mutants Y-N Fu et al ( Figure 4a ). As a control, all double mutants showed diminished phosphorylation at Y869 (845) (Figure 4b) , as detected by a pY845-selective antibody. These data suggested that Y869(845) phosphorylation by Src was important for maintaining the activation status of overexpressed EGFR proteins; however, S768I and L861Q mutants were less dependent on phosphorylation at Y869 (845) for their activation.
PP2 shows different growth-suppressive effects on 32D cells expressing EGFR variants Previously, we established 32D cell lines expressing mutated EGFRs to examine the epidermal growth factor (EGF)/EGFR-dependent cell proliferation (Chen et al., 2006) . We utilized this system to examine the ability of PP2 in suppressing cell proliferation supported by EGFR variants. Cells expressing L858R or deletion EGFR mutant were most sensitive to PP2. In comparison, cells expressing S768I and L861Q mutant are more resistant to PP2 (Figure 5a ). Therefore, the inhibitory effects of PP2 on receptor auto-phosphorylation and receptor-mediated cell proliferation are consistent among the EGFR variants (Figures 1 and 5a ). We also tested how Y869 (845) Figure 5) . While PP2 suppressed wild-type EGFR phosphorylation in H1299 cells (Figure 1) , it did not efficiently suppress 32D cells expressing wild-type EGFR (Figure 5a) . One difference between the experiments was that EGF was added in the 32D culture condition but not in the H1299 system. To determine whether this was the cause of discrepancy, we examined the effect of PP2 on receptor phosphorylation in 32D cells expressing wild-type, L858R or deletion EGFR. In the presence of EGF, the activation (phosphorylation) of wild-type EGFR indeed was resistant to PP2. In contrast, the phosphorylation of L858R and deletion mutants was The tyrosine phosphorylation of EGFR variants at Y1068 (a) and Y869 (845) (b) was examined by western blotting using specific antibodies. EGFR expression levels were determined using an anti-myc antibody. The intensity of the signals was determined by densitometry. The normalized phosphorylation levels were obtained by dividing the intensity of tyrosine phosphorylation over EGFR expression levels (a). EGFR, epidermal growth factor receptor. 
Gefitinib-resistant EGFR-deletion/T790M mutant is sensitive to PP2
Additional T790M mutation causes resistance to gefitinib or erlotinib in EGFR mutants that were initially sensitive to these inhibitors (Kobayashi et al., 2005; Kwak et al., 2005; Pao et al., 2005) . We tested whether EGFR-L858R and deletion mutants remained sensitive to PP2 in the presence of T790M mutation. As expected, T790M mutation rendered the L858R and exon 19 deletion mutants insensitive to gefitinib (Figure 6a ). Interestingly, L858R/T790M double mutant became resistant to PP2 in H1299 cells, while EGFR with exon 19 deletion/ T790M mutation seemed remain sensitive to PP2 in comparison to wild-type EGFR (Figure 6b ). Similar cellular responses were observed in 32D cells expressing these EGFR mutants. T790M mutation caused resistance to gefitinib either in the presence or absence of other mutations (Figure 7a ). T790M and L858R/T790M mutant-expressing 32D cells were resistant to PP2. Interestingly, the deletion/T790M mutant expressing 32D cells were relatively sensitive to PP2 (Figure 7b ), although the deletion/T790M mutant was more resistant to PP2 in comparison to the EGFR-deletion mutant. The effects of PP2 on the phosphorylation of EGFR variants with T790M mutation (Supplementary Figure 6a) were consistent with the result of viability tests. This differential effect was not due to different inhibitory effects on Src kinases in 32D derivatives, because PP2 had similar dose-inhibitory ability against Src family kinases, Fyn and Hck, in 32D cells with wild type, deletion (Del) or deletion/T790M EGFR, as determined by western blotting using an anti-pan-phospho-Src (Y416) antibody (Supplementary Figure 6b) . Varied sensitivity to Src suppression in EGFR mutants Y-N Fu et al
Discussion
Previously, we have characterized various EGFR mutants identified from NSCLC patients. All of the tested mutants showed constitutive phosphorylation in the absence of exogenous ligand stimulation (Chen et al., 2006) . In this study, we found that clinically identified EGFR mutants had different sensitivity to suppression of Src by an inhibitor PP2. Other reports have shown that phosphorylation at Y869(845) by Src is critical for optimal biological activity induced by EGF/ EGFR signaling (Biscardi et al., 1999 (Biscardi et al., , 2000 . However, the importance of Src and phosphorylation of EGFR at Y869(845) in the process of EGFR activation is not entirely clear. Phosphorylation at Y869(845)-similar residue in other receptor tyrosine kinases, for example FGFR and insulin receptor, is critical in keeping the activation loop of kinase domain in an opened position (Biscardi et al., 2000) . However, crystal structure analysis indicated that phosphorylation on Y869 (845) is not required for the positioning of activation loop of EGFR to maintain the opened structure (Stamos et al., 2002) . It has been proposed that under physiological condition, which is not fully represented by the crystal structure of EGFR, phosphorylation of Y869 (845) could be involved in the position of activation loop in the active conformation (Burgess et al., 2003; Zhang et al., 2006) . In this study, we found that the phosphorylation of wild-type EGFR was abolished by PP2 in the absence of EGF. Interestingly, EGF-induced phosphorylation of wild-type EGFR was much less sensitive to PP2 treatment (Figures 1, 3 and 5) . It remains to be examined whether this result implies that wild-type EGFR maintains its phosphorylation levels through different mechanisms in the presence and absence of ligand stimulation. We also found that, different from wild-type and other mutated EGFRs, S768I and L861Q mutants were less dependent on Src activity for their activation. This notion was first supported by the higher resistance of S768I and L861Q mutant against PP2 treatments (Figures 1 and  3) . Furthermore, the additional mutation at Y869(845), the Src phosphorylation site, had little effect on the receptor auto-phosphorylation in EGFR-S768I or L861Q mutants (Figure 4 ). Our data suggested that these two mutants become constitutively active through Src-independent activation of the receptor. Residue L861 locates at the EGFR activation loop. The S768 residue, which locates at the end of aC helix of kinase domain, is in close proximity to L861 in three-dimension structure (Supplementary Figure 1) . It is possible that mutations at these two residues favor the position of activation loop at an active conformation even in the absence of Y869(845) phosphorylation. We also found that L858R and exon 19 deletion mutants were more sensitive to Src suppression than wild-type EGFR and other mutant receptors. This differential hypersensitivity to PP2 could be detected in both receptor and cellular levels and remained unchanged when Y869(845)F mutants was introduced into the receptor variants. Src phosphorylates EGFR on multiple tyrosine residues including some locate in or near the kinase domain (Stover et al., 1995; Biscardi et al., 1999) . Although the mechanism of hypersensitivity in L858R and deletion mutants to Src suppression was unclear, it is likely that dependence on Src of these mutants was not only mediated through Y869(845) phosphorylation. Our result is also consistent with two recent reports showing that different Src inhibitors can efficiently inhibit EGFR-L858R and deletion mutants (Song et al., 2006; Zhang et al., 2007) .
T790M mutation causes resistance to EGFR targeting inhibitor (Pao et al., 2004 (Pao et al., , 2005 Kobayashi et al., 2005) . PP2 targets Src, which is involved in EGFR signaling, but not to EGFR per se. Under the speculation that double mutated EGFR would inherit the PP2 hypersensitivity, we tested whether PP2 could inhibit EGFR-L858R and exon 19 deletion mutants in the context of T790M mutation. Our results showed that L858R/ T790M double mutants become resistant to PP2. This result was consistent with the reports showing that H1975 NSCLC cell line, which containing EGFR-L858R/T790M, was resistant to Src inhibitors (Song et al., 2006; Zhang et al., 2007) . Interestingly, gefitinibresistant deletion/T790M double mutant remained relatively sensitive to PP2. Previously, we have found that EGFR-L858R and deletion mutants differed in their responsiveness to EGF stimulation (Chen et al., 2006) . Our results further revealed that L858R and deletion mutants, although both were sensitive to PP2, behaved differently under Src suppression in the presence of an additional T790M mutation.
Discovering the mechanism underlying clinical sensitivity to EGFR inhibitors holds great hope for identifying patients who will respond to EGFR-targeting therapy. However, variable responses to EGFR-targeting therapy, potentially raised from the diverse mutation patterns and genetic backgrounds in NSCLC patients, posed a challenge in selection of suitable patients (Hsieh et al., 2006) . Resistance to EGFR-targeting agents resulted from a secondary T790M mutation is also an urgent issue to be addressed (Kobayashi et al., 2005; Kwak et al., 2005; Pao et al., 2005) . Our results clearly showed that different EGFR mutants become constitutively active through distinct mechanisms; therefore, they have different biochemical properties and may respond differently to EGFR-targeting agents. Elucidating the activating mechanism(s) of EGFR mutants should provide a better understanding of EGFR mutation-triggered NSCLC and facilitate the development of therapeutic agents. Our data also indicated that suppression of Src could be an alternative approach in treatment of NSCLC harboring specific types of mutated EGFR.
Materials and methods
Cell culture, transfection and plasmids Culture and transfection of H1299 and 32D cells were performed as described previously (Chen et al., 2006) . The pcDNA4/TO/myc-His B vector (Invitrogen, Carlsbad, CA, USA)-based expression plasmids of EGFR variants were described previously (Chen et al., 2006) . The mutation sites were numbered according to the full-length sequence, including the signal peptide, of EGFR. All the EGFR point mutation variants were generated using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The expression vectors for all the EGFR variants were verified by DNA sequencing. All EGFR variants had a Myc-tagged epitope at their carboxyl termini.
Reagents and antibodies EGF was purchased from Sigma-RBI (Natick, MA, USA). The anti-myc monoclonal antibody was prepared from a culture of hybridoma clone 9E10 (American Type Culture Collection; Manassas, VA, USA). The anti-Src and antiphospho-EGFR (pEGFR) (Y845) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and from AbCam (Cambridge, UK), respectively. The other antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). BS 3 and peroxidase-conjugated antimouse IgG secondary antibody was purchased from Pierce (Rockford, IL, USA). Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes (Zhunan, Taiwan) provided gefitinib. PP2 and AG1478 were purchased from Calbiochem (San Diego, CA, USA). The other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).
Cell extracts preparation and immunoprecipitation
Cell extract was prepared by suspending 2 Â 10 6 cells in 200 ml of lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and 1 mM Na 3 VO 4 ). The cell extracts were incubated on ice with vigorous mixing every 5 min for four times. The extract was subjected to centrifugation at 15 000 g for 10 min, and the supernatant was collected for further analysis or stored at À801C. Immunoprecipitation was performed as described previously (Chen et al., 2006) .
Kinase assay, western blot analysis and cell viability assay The immunoprecipitated complexes were washed once with kinase buffer (20 mM 4-morpholinepropane-sulfonic acid (MOPS; pH 7.6), 2 mM EGTA, 10 mM MgCl 2 , 1 mM dithiothreitol, 0.1% Triton X-100 and 0.1 mM Na 3 VO 4 ), then mixed with 50 ml of kinase buffer containing the indicated substrate and 1.5 mM of ATP in the presence or absence of 10 mCi [g-32 P] ATP. The kinase reaction was performed at 371C for 30 min, and then was terminated by adding SDS sample buffer. The reaction mixtures were heated at 951C for 5 min and analysed by SDS-polyacrylamide gel electrophoresis and western blot analyses (or autoradiography). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay for cell viability and western blot analyses were performed as described previously (Chen et al., 2006) .
Abbreviations
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